Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Weifei Ye"'
Autor:
Thomas E. Hutson, M. Dror Michaelson, Ran Xie, Ana M. Molina, Mayer Fishman, Ulka N. Vaishampayan, Neeraj Agarwal, Urmi Bapat, Weifei Ye, Rohit Jain, James J. Hsieh, Timothy M. Kuzel
Publikováno v:
European Urology. 80:162-170
Background Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the treatment of advanced RCC after on
Autor:
Eric J. Sherman, Yann Godbert, Weifei Ye, Martin Schlumberger, Christopher M. Nutting, Lisa Licitra, Marcia S. Brose, Ran Xie, Kate Newbold, Soamnauth Misir, Maria E. Cabanillas, Lori J. Wirth, Steven I. Sherman, Keith C. Bible, Bruce G. Robinson, Patrice Rodien, Ana Almonte, Christelle De La Fouchardiere
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(21)
PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions. Lenvatinib is US Food and Drug Ad
Autor:
Marcia S. Brose, Ana Almonte, Weifei Ye, Martin Schlumberger, Maria E. Cabanillas, Lori J. Wirth, Sharon Xie, Soamnauth Misir, Eric J. Sherman, Lisa Licitra, Steven I. Sherman
Publikováno v:
Journal of the Endocrine Society
Background: ATC is aggressive, with a low 5-year patient (pt)-survival rate. Apart from recent advances in treating ATCs in pts with BRAF mutations, systemic treatments have limited efficacy and duration of response is short. In a small, phase 2 stud